Licensing status

Publication and contact information


Nuclear localization status of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2) to distinguish essential thrombocythemia (ET) and primary myelofibrosis (MF)

The nuclear localization status of NRF2 could help differentiate between the myeloproliferative disorders ET and primary MF. In patient biopsies, anti-NRF2 antibodies showed less than 17% nuclear NRF2 localization in erythroid cells from ET samples and greater than 27% nuclear NRF2 localization in erythroid cells from primary MF samples. Computational analysis of the biopsy data sets using NRF2 nuclear localization-based cutoff values distinguished between ET and primary MF with 92% accuracy. Next steps could include testing the method in patients with unclassifiable myeloproliferative disorders.

SciBX 6(24); doi:10.1038/scibx.2013.613
Published online June 20, 2013

Patent and licensing status unavailable

Aumann, K. et al. Blood; published online May 13, 2013;
Contact: Heike L. Pahl, University Medical Center Freiburg,
Freiburg, Germany